NASDAQ:ADIL

Adial Pharmaceuticals Stock Forecast, Price & News

$2.18

-0.20 (-8.40 %)

(As of 04/12/2021 12:00 AM ET)

Add

Compare

Today's Range

$2.15

Now: $2.18▼

$2.36

50-Day Range

$2.12

MA: $2.47▼

$3.13

52-Week Range

$1.14

Now: $2.18▼

$4.00

Volume271,423 shs

Average Volume644,265 shs

Market Capitalization$37.65 million

P/E RatioN/A

Dividend YieldN/A

Beta0.74

Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a selective serotonin-3 antagonist, which is in phase 3 clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. The company was founded in 2010 and is based in Charlottesville, Virginia.

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ADIL

Previous Symbol

CUSIPN/A

CIK1513525

Webwww.adialpharma.com

Phone434-422-9800

Employees8

Year FoundedN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio7.48

Quick Ratio7.48

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.69 per share

Price / Book3.16

Profitability

EPS (Most Recent Fiscal Year)N/A

Net Income$-8,590,000.00

Net MarginsN/A

Return on Equity-132.76%

Return on Assets-121.28%

Miscellaneous

Outstanding Shares17,270,000

Market Cap$37.65 million

Next Earnings Date5/13/2021 (Estimated)

OptionableNot Optionable

Headlines

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Insider Bankole A. Johnson Sells 150,000 Shares
April 8, 2021 | americanbankingnews.com

Adial Pharma Seeks To Treat The Pandemic Of Addiction
April 7, 2021 | finance.yahoo.com

Contrasting Adial Pharmaceuticals (NASDAQ:ADIL) & Tricida (NASDAQ:TCDA)
March 24, 2021 | americanbankingnews.com

Adial Pharmaceuticals to Participate at the Benzinga Biotech Small Cap Conference on March 24th
March 23, 2021 | finance.yahoo.com

Adial Founder and Chief Medical Officer Dr. Bankole Johnson Featured Guest on The Black News Channel
March 17, 2021 | finance.yahoo.com

Adial Announces Management-Led $2,100,000 Above Market Private Placement at $3.00 Per Share
March 15, 2021 | finance.yahoo.com

Adial Schedules Town Hall to Discuss Positive Updates Regarding Pharmaceutical Pipeline and Business Expansion
February 26, 2021 | finance.yahoo.com

Adial Receives $1.425 Million in Net Proceeds from Exercise of Warrants
February 26, 2021 | benzinga.com

Adial Pharmaceuticals Achieves 50% Enrollment in ONWARD™ Phase 3 Trial
February 25, 2021 | finance.yahoo.com

Adial to File Fast Track Application for AD04 with the FDA
February 23, 2021 | finance.yahoo.com

Adial Pharmaceutical, Inc.: Adial Pharmaceuticals Closes Acquisition of Purnovate
January 26, 2021 | finanznachrichten.de

Adial Pharmaceuticals Closes Acquisition of Purnovate
January 26, 2021 | finance.yahoo.com

Adial Pharmaceutical, Inc.: Adial Pharmaceuticals to Present at 23rd Annual ICR Conference
January 11, 2021 | finanznachrichten.de

Adial Pharmaceuticals Receives Notice of Allowance for Third U.S. Patent Covering AD04 for the Treatment for Opioid Use Disorder
January 11, 2021 | finance.yahoo.com

Adial Pharmaceuticals to Present at 23rd Annual ICR Conference
January 11, 2021 | finance.yahoo.com

Adial Pharmaceuticals Inc
December 19, 2020 | bloomberg.com

Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol
December 19, 2020 | bloomberg.com

Adial Pharmaceuticals Reaches 35% Enrollment in ONWARD(TM) Pivotal Phase 3 Trial of AD04 for the Treatment of Alcohol Use Disorder
December 17, 2020 | finance.yahoo.com

Adial Pharmaceuticals Appoints Dr. Jack Reich as Head of Regulatory
December 15, 2020 | finance.yahoo.com

See More Headlines

MarketRank^™

Overall MarketRank^™

0.40 out of 5 stars

Medical Sector

1746th out of 2,016 stocks

Pharmaceutical Preparations Industry

705th out of 771 stocks

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Adial Pharmaceuticals.

2.0 Community Rank

Outperform Votes
Adial Pharmaceuticals has received 95 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Adial Pharmaceuticals has received 140 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Adial Pharmaceuticals has received 59.57% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Adial Pharmaceuticals and other stocks. Vote “Outperform” if you believe ADIL will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ADIL will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Adial Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Adial Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adial Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $375,000.00 in company stock.
Percentage Held by Insiders
Only 33.90% of the stock of Adial Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 4.80% of the stock of Adial Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Adial Pharmaceuticals is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adial Pharmaceuticals is -2.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Adial Pharmaceuticals has a P/B Ratio of 3.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$2.18

-0.20 (-8.40 %)

(As of 04/12/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ADIL News and Ratings via Email

Sign-up to receive the latest news and ratings for ADIL and its competitors with MarketBeat's FREE daily newsletter.

Adial Pharmaceuticals (NASDAQ:ADIL) Frequently Asked Questions

What stocks does MarketBeat like better than Adial Pharmaceuticals?

Wall Street analysts have given Adial Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Adial Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Adial Pharmaceuticals' next earnings date?

Adial Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Adial Pharmaceuticals.

How has Adial Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Adial Pharmaceuticals' stock was trading at $1.35 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, ADIL shares have increased by 61.5% and is now trading at $2.18.
View which stocks have been most impacted by COVID-19.

Who are Adial Pharmaceuticals' key executives?

Adial Pharmaceuticals' management team includes the following people:

Mr. William B. Stilley III, M.B.A., MBA, Chairman, Pres & CEO (Age 53, Pay $614.1k)
Dr. Bankole A. Johnson DSc, Ph.D., M.D., M.Phil, FRCPsych, Founder & Chief Medical Officer (Age 61, Pay $375k)
Mr. Joseph M. Truluck M.B.A., MBA, CFO, COO, Treasurer & Sec. (Age 43, Pay $225.03k)
Dr. Jack W. Reich, Head of Regulatory (Age 72, Pay $17.01k)
Mr. Alex Lugovoy, Chief Bus. Officer
Mr. Mark H. Peikin, Chief Strategy Officer
Mr. Lawrence Goldman, Controller (Age 65)

Who are some of Adial Pharmaceuticals' key competitors?

Some companies that are related to Adial Pharmaceuticals include Aquestive Therapeutics (AQST), Lotus Pharmaceuticals (LTUS), Concert Pharmaceuticals (CNCE), NeuBase Therapeutics (NBSE), Evofem Biosciences (EVFM), Enochian Biosciences (ENOB), Adamas Pharmaceuticals (ADMS), Eyenovia (EYEN), Citius Pharmaceuticals (CTXR), Palatin Technologies (PTN), Odonate Therapeutics (ODT), GlycoMimetics (GLYC), Hepion Pharmaceuticals (HEPA), Liminal BioSciences (LMNL) and Synlogic (SYBX).
View all of ADIL's competitors.

What other stocks do shareholders of Adial Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu Biopharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP).

When did Adial Pharmaceuticals IPO?

(ADIL) raised $8 million in an IPO on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager.

What is Adial Pharmaceuticals' stock symbol?

Adial Pharmaceuticals trades on the NASDAQ under the ticker symbol "ADIL."

How do I buy shares of Adial Pharmaceuticals?

Shares of ADIL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Adial Pharmaceuticals' stock price today?

One share of ADIL stock can currently be purchased for approximately $2.18.

How much money does Adial Pharmaceuticals make?

Adial Pharmaceuticals has a market capitalization of $37.65 million.

How many employees does Adial Pharmaceuticals have?

Adial Pharmaceuticals employs 8 workers across the globe.

What is Adial Pharmaceuticals' official website?

The official website for Adial Pharmaceuticals is www.adialpharma.com.

Where are Adial Pharmaceuticals' headquarters?

Adial Pharmaceuticals is headquartered at 1180 Seminole Trail Suite 495, Charlottesville VA, 22901.

How can I contact Adial Pharmaceuticals?

Adial Pharmaceuticals' mailing address is 1180 Seminole Trail Suite 495, Charlottesville VA, 22901. The company can be reached via phone at 434-422-9800 or via email at [email protected]

This page was last updated on 4/13/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here